



National
COVID
Cohort
Collaborative

National COVID Cohort Collaborative (N3C) Data Exchange For Emerging/Novel Diseases (DEFEND)

Internal Team

Rob Star, NIDDK

Ken Gersing, NCATS

Stephen Hewitt, LP, NCI

Michael Kurilla, NCATS

Sam Michael, NCATS


Joni Rutter, NCATS

External Imaging Advisors

Fred Prior, U of Arkansas for Medical Sciences


Joel Saltz, SUNY/Stony Brook

Re-engineering Clinical Research




Typical NIH Network

Academic Health Center Sites & Data Coordinating Center




Interoperable Networks Share Sites and Data



Integration of Clinical Research Networks

- Link existing networks so clinical studies and trials can be conducted more effectively
- Ensure that patients, physicians, and scientists form true “Communities of Research”





Re-engineering the Clinical Research Enterprise



Increasing Level of Difficulty

<p>Plan and start a few demonstration networks</p> <p>Simplify complex regulatory systems – demonstration projects</p> <p>Plan for networks in place for all institutes</p>	<p>Funding mechanism to sustain national system through consensus of all constituents (“1% solution”)</p> <p>Simplified regulatory system in place for networks</p>	<p>National Clinical Research System creates effectiveness data that moves rapidly into the community AND data on outcomes and quality of care; sustained efficient infrastructure to rapidly initiate large clinical trials; scientific information for patients, families, advocacy groups</p>
<p>Establish repositories of biological specimens and standards for collection</p> <p>Standardize nomenclature, data standards, core data, forms for most major diseases</p> <p>Start a library of these elements shared between institutes and NLM</p> <p>Develop efficient network administration infrastructure at NIH</p> <p>Develop standards for capturing images for research</p>	<p>Data standards shared across NIH institutes</p> <p>Funding mechanisms evaluated to determine which are most efficient</p>	<p>ONE medical nomenclature with national data standards (agreed to by NIH, CMS, FDA, DOD, CDC)</p> <p>Data standards updated “in real time” through networks</p> <p>National repository of images and samples</p> <p>Critical national “problem list”</p> <p>Most efficient network funding mechanisms in place across NIH</p>
<p>Create NIH standards to provide “safe haven” for clinical research</p> <p>Inventory and evaluate existing public-private partnerships, networks, CR institutions, and regulatory systems</p> <p>Establish FORUM(S) of <u>all</u> stakeholders</p> <p>Establish standards for and pilot creation of a National Clinical Research Corps</p> <p>Demonstration/planning grants to enhance/evaluate/develop model networks</p>	<p>NIH standards for safe haven in place</p> <p>Regulations and ethics harmonized with FDA, CMS</p> <p>Public private partnership mechanisms in place</p> <p>100,000 members of certified “Clinical Research Corps”</p> <p>Standards shared across NIH</p>	<p>Participation in research is a professional standard (taught in all health professions schools)</p> <p>Study, evaluation and training regarding clinical research a part of every medical school, nursing school, pharmacy school</p> <p>Clinical research practices documented and updated regularly to maintain safe haven</p> <p>Networks provide detailed training about network specific issues</p>

1-3 years

4-7 years
Time

8-10 years

2002-3



Re-engineering the Clinical Research Enterprise



Increasing Level of Difficulty

<p>Plan and start a few demonstration networks</p> <p>Simplify complex regulatory systems – demonstration projects</p> <p>Plan for networks in place for all institutes</p>	<p>Funding mechanism to sustain national system through consensus of all constituents (“1% solution”)</p> <p>Simplified regulatory system in place for networks</p>	<p>National Clinical Research System creates effectiveness data that moves rapidly into the community AND data on outcomes and quality of care; sustained efficient infrastructure to rapidly initiate large clinical trials; scientific information for patients, families, advocacy groups</p>
<p>Establish repositories of biological specimens and standards for collection</p> <p>Standardize core data, form</p> <p>Start a library between institu</p> <p>Develop efficient infrastructure a</p> <p>Develop standard research</p>	<p>Data standards shared across NIH institutes</p>	<p>ONE medical nomenclature with national data standards (agreed to by NIH, CMS, and “in real time”)</p> <p>Images and samples are on a common list”</p> <p>funding mechanisms</p>
<p>Create NIH “safe haven” for clinical research</p> <p>Inventory and evaluate existing public-private partnerships, networks, CR institutions, and regulatory systems</p> <p>Establish FORUM(S) of all stakeholders</p> <p>Establish standards for and pilot creation of a National Clinical Research Corps</p> <p>Demonstration/planning grants to enhance/evaluate/develop model networks</p>	<p>FDA, CMS</p> <p>Public private partnership mechanisms in place</p> <p>100,000 members of certified “Clinical Research Corps”</p> <p>Standards shared across NIH</p>	<p>Study, evaluation and training regarding clinical research a part of every medical school, nursing school, pharmacy school</p> <p>Clinical research practices documented and updated regularly to maintain safe haven</p> <p>Networks provide detailed training about network specific issues</p>

1-3 years

4-7 years
Time

8-10 years

2002-3



Re-engineering the Clinical Research Enterprise



Increasing Level of Difficulty

<p>Plan and start a few demonstration networks</p> <p>Simplify complex regulatory systems – demonstration projects</p> <p>Plan for networks in place for all institutes</p>	<p>Funding mechanism to sustain national system through consensus of all constituents (“1% solution”)</p> <p>Simplified regulatory system in place for networks</p>	<p>National Clinical Research System creates effectiveness data that moves rapidly into the community AND data on outcomes and quality of care; sustained efficient infrastructure to rapidly initiate large clinical trials; scientific information for patients, families, advocacy groups</p>
<p>Establish repositories of biological specimens and standards for collection</p> <p>Standardize core data, form</p> <p>Start a library between institu</p> <p>Develop efficient infrastructure a</p> <p>Develop standard research</p>	<p>Data standards shared across NIH institutes</p>	<p>ONE medical nomenclature with national data standards (agreed to by NIH, CMS, and “in real time”)</p> <p>Images and samples are on a common list”</p> <p>Funding mechanisms</p>
<p>Create NIH “safe haven” for clinical research</p> <p>Inventory and create a common data element for private partner institutions, and regulatory systems</p> <p>Establish FORUM(S) of all stakeholders</p> <p>Establish standards for and pilot creation of a National Clinical Research Corps</p> <p>Demonstration/planning grants to enhance/evaluate/develop model networks</p>	<p>Place a</p> <p>100,000 members of certified “Clinical Research Corps”</p> <p>Standards shared across NIH</p>	<p>There is a professional health professions training regarding clinical research a part of every medical school, nursing school, pharmacy school</p> <p>Clinical research practices documented and updated regularly to maintain safe haven</p> <p>Networks provide detailed training about network specific issues</p>

1-3 years

4-7 years
Time

8-10 years

NCATS

COLLABORATE. INNOVATE. ACCELERATE.

National COVID Cohort Collaborative (N3C)

7/2020





Goals – Version 2.0

Rapidly collect and aggregate clinical, lab, and imaging **data** from **hospitals, health plans, and CMS** at the **peak of the pandemic** and as it **evolves**

- Provide a **longitudinal dataset** to understand acute **hospital** and **recovery** phases

- Understand **pathophysiology** of disease

- Support **clinical trials** – identify patients who might wish to participate in trials

Develop a **robust, flexible infrastructure** to enable rapid response to COVID-19 and the next emerging threats


- Speed is critical; leverage existing infrastructure;** poised to collect data immediately

- Analytics platform should be non-proscriptive and easily reconfigurable

- Must be able to interconnect to numerous data streams and analytic resources



N3C Overview



1

Data partnership &
governance

2

Data acquisition &
Phenotype

3


Data ingest &
harmonization

4

Collaborative analytics &
FAIR Sharing/Credit

Federated versus Centralized Analytical Models: Characteristics

Federated Model



Is **drug X** beneficial to covid-19 patients?
Does **Disease Y** impair course?
Does an **income** > \$50,000 per year improve outcomes?

Centralized Model



What **drugs** help covid-19 patients, and which hinder?
What **Diagnoses** impact outcome?
What **Social Determinants** impact course and outcome?



N3C Community Workstreams

**Data Partnership
and Governance**



**Phenotype and
Data Acquisition**



**Data Ingestion
and Harmonization**



**Collaborative
Analytics**



**Synthetic
Data**



NCATS N3C website: ncats.nih.gov/n3c

CD2H N3C website: covid.cd2h.org

Onboarding to N3C: bit.ly/cd2h-onboarding-form



NATIONAL CENTER
FOR DATA TO HEALTH



National Center
for Advancing
Translational Sciences



National
COVID
Cohort
Collaborative



National Center
for Advancing
Translational Sciences

N3C Statistics

7/8/2020

48 DTAs executed

27 IRB protocols approved (23 reliance, 4 local)

24 Regulatory complete (both DTA and IRB)

36 Met with Data Acquisition Group

.....9 Deposited data:

.....4 - PCORI

.....3 - OMOP

.....1 - TriNetX

.....1 - ACT

**CTSA
Organizations**

85%

N3C Organizations

105

**N3C Individual
Members**

800



Data Partnership and Governance


Goal of the Data Use Agreement is broad access:

- COVID-Related research only
- **Open platform to all Credentialed researchers**
- Security: Activities in the N3C Enclave are recorded and can be audited
- Disclosure of research results to the N3C Enclave for the public good
- Analytics provenance
- Contributor Attribution tracking
- No download of data





Regulatory overview





Data Tiers

Access Level	Registered	Controlled		Controlled-Plus	
Data Type	Synthetic Data (pending pilot)	Aggregate Data (i.e., counts)	HIPAA Safe Harbor	HIPAA Limited	
Description	Computational data derivative that statistically resembles the original data	Counts and summary statistics representing 10 or more individuals	Data stripped of 18 direct identifiers per HIPAA rules	Data that may contain 3 direct identifiers per HIPAA rules (dates, full zip code, and any age)	
Capabilities					
Downloadable data	Planned: pending validation & organizational agreement	Downloadable query results	No	No	
Custom software	Yes	Yes - on downloaded query results	Yes with DAC approval	Yes - with independent IRB and DAC approval	




Phenotype & Acquisition

Dual-purpose workflow:

1. Work with the community to write and maintain a computable phenotype for COVID-19.
2. Write and maintain a series of scripts to execute the computable phenotype in each of four common data models (CDMs): OMOP, i2b2/ACT, PCORnet, and TriNetX.

What does it look like to run our process locally?



Support is available for all parts of this process!

Latest phenotype: covid.cd2h.org/phenotype

Documentation: covid.cd2h.org/phenotype-wiki

All specifications and software shared on GitHub






Common Data Model Harmonization



ADEPTIA
Workflow



	Verification				Validation				Total			
	Pass	Fail	Total	% Pass	Pass	Fail	Total	% Pass	Pass	Fail	Total	% Pass
Plausibility	159	21	180	88%	283	0	283	100%	442	21	463	95%
Conformance	637	34	671	95%	104	0	104	100%	741	34	775	96%
Completeness	369	17	386	96%	5	10	15	33%	374	27	401	93%
Total	1165	72	1237	94%	392	10	402	98%	1557	82	1639	95%



Data Quality Dashboard (shared with site)

First Stage Ingestion


- Unpack Zip'ed csv Files. Check data manifests ✓
- Reconstitute into native CDM formats ✓ ?
- Hybrid Data Quality checks adapting OHDSI Data Quality Dashboard ✓ ?



National Center
for Advancing
Translational Sciences



Data Quality Gates






NCATS, FDA, and NCI working together on CDM harmonization


Harmonization of Common data models, (PCORMET, Sentinel, OMOP, ACT) FHIR / USCORE and CDISC

Meta data initiative makes the meaning of data publicly available and reusable in **human and machine-readable**





Collaborative Analytics - N3C Secure Data Enclave






Collaborative Analytics - N3C Secure Data Enclave



AWS GovCloud (US)



Clinical Scenarios

AKI/ARB/ACE

Critical Care

**Short/Long term
Complications**

Diabetes

Pregnancy

Social Determinants of Health

**Immuno-suppressed/
Compromised**

Elder Impact

Oncology

Pediatrics

Population Health/Health Policy

Emergency Dept Avoidance Impact






Cohort Characterisation

Cohort characteristics

Summary statistics for WUSTL patients

	COVID (N=1161)	Non-COVID (N=5904)	Overall (N=7065)
Gender			
Male	1059	7022	2141
Female	1091	8069	9160
Null		3	3
Age			
0 - 17	46	2095	2141
18 - 29	303	2043	2346
30 - 49	616	3638	4254
50 - 64	584	3488	4072
65+	523	3498	4021
Race			
White	614	8110	8724
Asian	127	1225	1352
American Indian or Alaska Native	5	27	32
Black or African American	1083	3693	4776
Other Pacific Islander	1	7	8
Null	306	1958	2264
Ethnicity			
Not Hispanic or Latino	1926	13910	15836
Hispanic or Latino	165	984	1149
Unknown	59	200	259

To plot: Condition





Time/Space Vector - Live Example

N3C

COVID-19 HOSPITAL VISITS



National Institutes
of Health



National
COVID
Cohort
Collaborative


Visits (Cumulative)
3041 VISITS

of Days Past 01/01/2020



Actions

Map View Analytics Another tab




Source	Count
Ancillary Department	1054
NS	1004
ER	411
Inpatient Hospital	284
Same Day Surgery	160
Clinic	122
Ancillary	5
Emergency	1



National Center
for Advancing
Translational Sciences



Predictive Modeling: Risk of Ventilation and AKI



Random forest model trained on 200 COVID-19 patients, 100 of whom required ventilation, and 100 did not. It performs well, with an AUC of 0.85. Shown are the top features in the model predicting ventilator usage as an outcome.



Using these features, we are able to see separation in a PCA plot between the ventilator population in orange and the non-ventilator population in blue.

Data Sharing Initiative: Synthetic Data

*Computer Derived Synthetic Data: Validation of Sepsis Prediction

Public / Private Partnership

- *Wash University*
- *Microsoft*
- *MDCClone*

		Trained on real data Tested on real data	Trained on synthetic data Tested on real data
Train	Accuracy	0.925	0.911
	Precision	0.95	0.925
	Recall	0.817	0.799
	F-Score	0.879	0.858
10-fold cross-validation	Accuracy	0.839	0.816
	Precision	0.802	0.754
	Recall	0.704	0.666
	F-Score	0.745	0.704
Test	Accuracy	0.846	0.841
	Precision	0.836	0.845
	Recall	0.671	0.645
	F-Score	0.745	0.731

ML model performance (random forest)

*Wash. U. Philip Payne





Partners, Teams, Collaborators

NCATS

Chris Austin
Joni Rutter
Mike Kurilla
Clare Schmitt
Ken Gersing
Xinzhi Zhang
Erica Rosemond
Sam Bozzette
Lili Portilla
Chris Dillon
Penny Burgoon
Emily Marti
Meredith Temple-
O'Connor
Sam Jonson
Christine Cutillo
Nicole Garbarini

NIH & HHS Partners

NCI
Janelle Cortner
Stephen Hewitt
Denise Warzel

FDA

Mitra Rocca
Scott Gideon
Wei Chen

NIDDK

Robert Star

NIGMS

Ming Lee

NCATS ITRB

Sam Michael
Mariam Deacy
Gary Berkson
Josephine Kennedy
Usman Sheikh
Mark Backus
Nam Ngo
Amit Virakatmath
Keats Kirsch
Sulochana Nunna
Rafael Fuentes
Reid Simon
Biju Mathew
Tim Mierzwa
Ke Wang
Kalle Virtaneva

CD2H

OHSU/OSU
Melissa Haendel
Anita Walden
Julie McMurtry
Moni Munoz-Torres
Andrea Volz
Connor Cook
Racquel Dietz
Andrew Neumann
Rich Lorimor

Sage Bionetworks

Justin Guinney
James Eddy

U of Iowa:

Dave Eichmann
Alexis Graves

Northwestern:

Kristi Holmes
Justin Starren
Lisa O'Keefe

Washington U.

Philip Payne
Albert Lai
Tom Dillon

CD2H

U. Of Washington
Adam Wilcox
Liz Zampino

Johns Hopkins U

Chris Chute
Tricia Francis

Jax Labs

Peter Robinson

Scripps

Chunlei Wu

Teams

Governance
Sage Bionetworks
John Wilbanks
Christine Suver

Data Harmonization

JHU
Davera Gabriel
Stephanie Hong
Harold Lehmann
Tanner Zhang
Richard Zhu

SAMVIT

Smita Hastak
Charles Yaghmour

NCATS

Raju Hemadri
Nancy Nurthen
Sai Manjula

Adeptia

Sandeep Naredla

Teams

Phenotype & Acquisition
Emily Pfaff, UNC

ACT

Michele Morris, Pitt
Shyam Visweswaran, Pitt
Shawn Murphy HRD

OMOP

Kristin Kostka, IQVIA
Karthik Natarajan, Columbia
Clare Blacketer JNJ

PCORI

Kellie Walters, UNC
Robert Bradford, UNC
Marshall Clark, UNC
Adam Lee, UNC
Evan Colmenares, UNC

TriNetX

Matvey Palchuk
Lora Lingrey

Teams

Analytics

Warren Kibbe, Duke
Heidi Sprait, UTMB
Tell Bennett, U of CO
Andrew Williams, Tufts
Joel Saltz, SBU
Janos Hajagos, SBU
Richard Moffitt, SBU
Tahsin Kurc, SBU

Palantir

Nabeel Qureshi
Andrew Girvin
Amin Manna

Synthetic Data

Regenstrief
Peter Embi

MDClone

Daniel Blumenthal
Hovav Dror
Luz Erez
Josh Rubel

Microsoft

Allison T Rodriguez
Kenji Takeda





National
COVID
Cohort
Collaborative

Thank you!





N3C 2.0: Key Focus Areas

Patient-focused

- Descriptive
 - Epidemiology (in non-hospitalized and hospitalized people)
 - Disparities (racial, ethnic, SES) – identification of risk; spread through communities
 - Disease course of hospitalized disease (subgroups)
 - Drugs – what tried, multiple drugs, association with outcomes
- Pathophysiology (from routinely collected data)
 - Causes of disease (lung injury, hypoxia, cytokine storm, thrombosis, cardiac, renal, etc), and subgroups
 - Which patients with Negative COVID test have COVID19 disease (false negative)?
- Predictors (supervised AI)
 - Predictors of hospitalization, prolonged hospitalization, mortality
 - Scoring systems for intervention (ventilation, dialysis)
 - How does imaging influence subgroups and predictions
- Special populations (subgroups; Latent class analysis; unsupervised AI)
 - Do poorly, different pathophys, respond differently to treatments, etc.
- Long term sequela (Post COVID19 syndromes: weakness, lung, brain, heart, kidney)

System-focused

- Hospital responses to COVID
- Effect of COVID on hospitals
- Economics


Patient Portal: Future studies, Track Recovery

Patient autonomy

- Opt in for future data synch (to show to other care givers)
- Opt in to get information about related clinical trials
- Once enrolled in a study, can Opt in to synch information for research studies
- Opt in to share information back

Track recovery

- Overall: how do you feel?
- Degree of return to usual activities (Physical, Mental)
- Degree of recovery to pre-baseline state of health
 - Subscales (strength, lung, ADL)
- Major symptoms
 - Smell, Breathing (SONG COVID scale); Cough
 - Pain (where), Thinking, Weakness,



**Green button:
Synergize Care and
Research**